(GENI) Generic Sweden publ - Ratings and Ratios
Messaging, Communication, Technology, Solutions, Platforms
GENI EPS (Earnings per Share)
GENI Revenue
Description: GENI Generic Sweden publ
Generic Sweden AB is a Swedish technology company specializing in messaging services and digital communication platforms. With a history dating back to 1993, the company has established itself as a key player in the IT consulting and services sector, headquartered in Stockholm, Sweden. For more information, visit their official website at https://www.generic.se. As a provider of messaging services for various applications, Generic Sweden ABs offerings cater to a broad range of digital communication needs.
Analyzing the companys stock, GENI, we observe that it is classified as a common stock under the GICS Sub Industry of IT Consulting & Other Services, originating from Sweden. This categorization places Generic Sweden AB within a specific investment universe, allowing for more targeted comparisons and analyses.
By examining the technical indicators, we can infer potential trends and price movements. Given the current Last Price of 55.80 SEK, the stock is below its SMA20 (58.88 SEK) and SMA50 (57.96 SEK), indicating a potential short-term downtrend. However, it remains above its SMA200 (51.75 SEK), suggesting a longer-term uptrend. The ATR of 1.98 SEK (or 3.55%) signifies moderate volatility. With the 52-week high and low at 61.80 SEK and 40.84 SEK, respectively, the stock is currently trading near the middle of its recent range. Combining these technical insights with fundamental data, such as a Market Cap of 737.52M SEK, a P/E ratio of 24.96, and a RoE of 57.88%, we can forecast the stocks potential performance.
Forecasting the stocks future movement involves integrating both technical and fundamental analyses. The relatively high RoE of 57.88% indicates strong profitability, which, combined with a P/E ratio of 24.96, suggests that the stock might be fairly valued or slightly overvalued, depending on future earnings growth expectations. Technically, a break above the SMA20 and SMA50 could signal a resumption of the uptrend, potentially targeting the 52-week high of 61.80 SEK. Conversely, failure to break through these resistance levels might lead to a retest of the SMA200 or lower. Therefore, a likely forecast is that GENI will experience a short-term correction or consolidation before potentially resuming its longer-term uptrend, driven by its strong fundamental performance.
GENI Stock Overview
| Market Cap in USD | 66m |
| Sub-Industry | IT Consulting & Other Services |
| IPO / Inception |
GENI Stock Ratings
| Growth Rating | 61.3% |
| Fundamental | 89.0% |
| Dividend Rating | 69.9% |
| Return 12m vs S&P 500 | -5.63% |
| Analyst Rating | - |
GENI Dividends
| Dividend Yield 12m | 3.07% |
| Yield on Cost 5y | 4.86% |
| Annual Growth 5y | 37.97% |
| Payout Consistency | 98.0% |
| Payout Ratio | 63.2% |
GENI Growth Ratios
| Growth Correlation 3m | -89.7% |
| Growth Correlation 12m | 58.6% |
| Growth Correlation 5y | 16.4% |
| CAGR 5y | 21.77% |
| CAGR/Max DD 3y | 0.65 |
| CAGR/Mean DD 3y | 2.17 |
| Sharpe Ratio 12m | -0.13 |
| Alpha | 0.23 |
| Beta | 0.669 |
| Volatility | 29.52% |
| Current Volume | 14k |
| Average Volume 20d | 16k |
| Stop Loss | 48.2 (-3.4%) |
| Signal | -1.20 |
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (31.2m TTM) > 0 and > 6% of Revenue (6% = 10.8m TTM) |
| FCFTA 0.36 (>2.0%) and ΔFCFTA 11.87pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 26.61% (prev 23.91%; Δ 2.71pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.43 (>3.0%) and CFO 36.2m > Net Income 31.2m (YES >=105%, WARN >=100%) |
| Net Debt (-22.2m) to EBITDA (40.1m) ratio: -0.55 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (12.3m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 27.46% (prev 20.66%; Δ 6.80pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 232.6% (prev 223.7%; Δ 8.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3918 (EBITDA TTM 40.1m / Interest Expense TTM 10.0k) >= 6 (WARN >= 3) |
Altman Z'' 10.82
| (A) 0.57 = (Total Current Assets 74.7m - Total Current Liabilities 26.8m) / Total Assets 83.7m |
| (B) 0.63 = Retained Earnings (Balance) 53.1m / Total Assets 83.7m |
| (C) 0.51 = EBIT TTM 39.2m / Avg Total Assets 77.4m |
| (D) 1.52 = Book Value of Equity 50.5m / Total Liabilities 33.2m |
| Total Rating: 10.82 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 88.97
| 1. Piotroski 8.50pt = 3.50 |
| 2. FCF Yield 4.98% = 2.49 |
| 3. FCF Margin 16.95% = 4.24 |
| 4. Debt/Equity 0.66 = 2.29 |
| 5. Debt/Ebitda 0.83 = 1.99 |
| 6. ROIC - WACC 49.86% = 12.50 |
| 7. RoE 58.12% = 2.50 |
| 8. Rev. Trend 93.95% = 4.70 |
| 9. Rev. CAGR 14.88% = 1.86 |
| 10. EPS Trend 70.90% = 1.77 |
| 11. EPS CAGR 11.36% = 1.14 |
What is the price of GENI shares?
Over the past week, the price has changed by -2.92%, over one month by -5.85%, over three months by -18.06% and over the past year by +13.55%.
Is Generic Sweden publ a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GENI is around 48.92 SEK . This means that GENI is currently overvalued and has a potential downside of -1.96%.
Is GENI a buy, sell or hold?
What are the forecasts/targets for the GENI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.6 | -88.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 54.3 | 8.9% |
GENI Fundamental Data Overview
Market Cap SEK = 617.1m (617.1m SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 37.2m SEK (Cash And Short Term Investments, last quarter)
P/E Trailing = 19.7638
P/S = 3.404
P/B = 12.3729
Beta = 0.76
Revenue TTM = 180.0m SEK
EBIT TTM = 39.2m SEK
EBITDA TTM = 40.1m SEK
Long Term Debt = 6.47m SEK (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 26.8m SEK (from totalCurrentLiabilities, last quarter)
Debt = 33.2m SEK (Calculated: Short Term 26.8m + Long Term 6.47m)
Net Debt = -22.2m SEK (from netDebt column, last quarter)
Enterprise Value = 613.1m SEK (617.1m + Debt 33.2m - CCE 37.2m)
Interest Coverage Ratio = 3918 (Ebit TTM 39.2m / Interest Expense TTM 10.0k)
FCF Yield = 4.98% (FCF TTM 30.5m / Enterprise Value 613.1m)
FCF Margin = 16.95% (FCF TTM 30.5m / Revenue TTM 180.0m)
Net Margin = 17.33% (Net Income TTM 31.2m / Revenue TTM 180.0m)
Gross Margin = 27.46% ((Revenue TTM 180.0m - Cost of Revenue TTM 130.6m) / Revenue TTM)
Tobins Q-Ratio = 12.15 (Enterprise Value 613.1m / Book Value Of Equity 50.5m)
Interest Expense / Debt = 0.03% (Interest Expense 10.0k / Debt 33.2m)
Taxrate = 20.67% (7.10m / 34.3m)
NOPAT = 31.1m (EBIT 39.2m * (1 - 20.67%))
Current Ratio = 2.79 (Total Current Assets 74.7m / Total Current Liabilities 26.8m)
Debt / Equity = 0.66 (Debt 33.2m / last Quarter total Stockholder Equity 50.5m)
Debt / EBITDA = 0.83 (Net Debt -22.2m / EBITDA 40.1m)
Debt / FCF = 1.09 (Debt 33.2m / FCF TTM 30.5m)
Total Stockholder Equity = 53.7m (last 4 quarters mean)
RoA = 37.27% (Net Income 31.2m, Total Assets 83.7m )
RoE = 58.12% (Net Income TTM 31.2m / Total Stockholder Equity 53.7m)
RoCE = 65.14% (Ebit 39.2m / (Equity 53.7m + L.T.Debt 6.47m))
RoIC = 57.91% (NOPAT 31.1m / Invested Capital 53.7m)
WACC = 8.05% (E(617.1m)/V(650.3m) * Re(8.48%)) + (D(33.2m)/V(650.3m) * Rd(0.03%) * (1-Tc(0.21)))
Shares Correlation 5-Years: -89.40 | Cagr: -0.08%
Discount Rate = 8.48% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.83% ; FCFE base≈25.3m ; Y1≈27.3m ; Y5≈33.6m
Fair Price DCF = 43.92 (DCF Value 539.9m / Shares Outstanding 12.3m; 5y FCF grow 8.75% → 3.0% )
Revenue Correlation: 93.95 | Revenue CAGR: 14.88%
Rev Growth-of-Growth: -5.14
EPS Correlation: 70.90 | EPS CAGR: 11.36%
EPS Growth-of-Growth: 21.49